Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment

Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2014, Pages 291-300

  Sidharta, Patricia N ^a   Lindegger, Nicolas ^a   Ulč, Ivan ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Cepha Sro   (Czech Republic)

Author keywords

endothelin receptor antagonist; hepatic function impairment; macitentan; pharmacokinetics; renal function impairment

Indexed keywords

ACT 132577; ACT 373898; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DRUG METABOLITE; GAMMA GLUTAMYLTRANSFERASE; MACITENTAN; UNCLASSIFIED DRUG; ENDOTHELIN RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL ARTICLE; COMMON COLD; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; KIDNEY DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLASMA PROTEIN BINDING; PROSPECTIVE STUDY; SEVERE HEPATIC IMPAIRMENT; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VOMITING; BLOOD; CLINICAL TRIAL; LIVER DISEASES; MIDDLE AGED; RENAL INSUFFICIENCY;

ADULT; AGED; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RENAL INSUFFICIENCY; SULFONAMIDES;

EID: 84898645285     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.193     Document Type: Article

References (28)

1. Iglarz M, Clozel M., Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol. 2007; 50 (6): 621-628. (Pubitemid 350307030)
2. Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE. 2012; 7 (10): e47662. doi: 10.1371/journal.pone.0047662
3. NCT00660179. Study of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. Clinical trials 2012; Available at: URL: http://clinicaltrials.gov/ct2/show/NCT00660179?term= seraphin&rank=2 Accessed 2013.
4. NCT01474122. Macitentan for the treatment of digital ulcers in systemic sclerosis patients (DUAL-2). Clinical trials 2012; available at: http://clinicaltrials.gov/ct2/show/NCT01474122?term=NCT01474122&rank=1 Accessed 2013.
5. NCT01499251. Macitentan in combo with dose-dense temozolomide in patients with recurrent glioblastoma. Clinical trials 2012; available at: http://clinicaltrials.gov/ct2/show/NCT01499251?term=NCT01499251&rank=1 Accessed 2013.
6. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369 (9): 809-818.
7. Sidharta PN, van Giersbergen PL, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011; 67 (10): 977-984.
8. Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012; 42 (9): 901-910.
9. Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013; 52 (8): 685-692.
10. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008; 327 (3): 736-745.
11. Bruderer S, Aanismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012; 14 (1): 68-78.
12. Bruderer S, Marjason J, Sidharta PN, et al. Pharmacokinetics of macitentan in Caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology. 2013; 91 (5-6): 331-338.
13. Sidharta PN, van Giersbergen PL, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects. Eur Respir J 2012; (Suppl 56): 165S.
14. Sidharta PN, Dietrich H, Dingemanse J., Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects. Eur Respir J 2012; (Suppl 56): 166S.
15. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60 (8): 646-649.
16. Cockroft DW, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41.
17. Gault MH, Longerich LL, Harnett JD, et al. Predicting glomerular function from adjusted serum creatinine. Nephron. 1992; 62 (3): 249-256.
18. Kummer O, Haschke M, Hammann F, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci. 2009; 38 (4): 384-388.
19. Sidharta PN, van Giersbergen PLM, Dingemanse J., Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol. 2013; 53 (11): 1131-1138.
20. U.S., Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (Revision 1). US Food and Drug Administration 2010; Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf
21. Verbeeck RK., Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008; 64 (12): 1147-1161.
22. Vanholder R, Van Landschoot N, De Smet R, et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988; 33 (5): 996-1004.
23. McLean AJ, Morgan DJ., Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet. 1991; 21 (1): 42-69.
24. van Giersbergen PLM, Popescu G, Bodin F, et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2003; 43 (1): 15-22. (Pubitemid 36015438)
25. Gilead. Ambrisentan. 2013; available at: http://www.gilead.com/=/media/ Files/pdfs/medicines/cardiovascular/letairis/letairis-pi.pdf Accessed may 30, 2013.
26. Actelion Registration Ltd. Tracleer. 2013; available at: http://www.tracleer.com/docs/Tracleer-Full-Prescribing-Information.pdf Accessed 2013.
27. Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J. 2013; 41 (1): 96-103.
28. Dingemanse J, van Giersbergen PLM., Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther. 2002; 40 (7): 310-316. (Pubitemid 34732808)